aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
17 avr. 2023 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
10 nov. 2022 16h00 HE
|
aTyr Pharma, Inc.
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value...
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
29 sept. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
15 août 2022 16h00 HE
|
aTyr Pharma, Inc.
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the...
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
09 mai 2022 16h00 HE
|
aTyr Pharma, Inc.
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod...
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting
11 avr. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
14 mars 2022 16h00 HE
|
aTyr Pharma, Inc.
FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022. Company ended 2021...
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
08 mars 2022 16h35 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
09 nov. 2021 08h05 HE
|
aTyr Pharma, Inc.
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
03 nov. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...